Novavax’s COVID-19 vaccine will be available in Poland from February 21. Nuvaxovid will be the fifth vaccine to be used in Poland and the first one based on classic protein technology. In December 2021, the European Commission approved Nuvaxovid on the market in the Union, for people aged 18 and over.

Wojciech Andrusiewicz, the spokesman of the Ministry of Health, announced at a press conference that 9.5 million vaccines should reach the entire European Union on February 21. Poland will be provided with 8% of this EU number, i.e. 700,000 vaccines.

Based on clinical trials, the effectiveness of the Novavax vaccine has been assessed at over 90% for the mild, moderate and severe forms of COVID-19 especially with regard to the original variant from Wuhan, as well as further variants – Alpha and Beta. Recent research shows that the vaccine produces antibodies that cross-react to other variants, including the Omicron.

Nuvaxovid is a vaccine that will also be produced in Poland. On Christmas Eve, the country’s first production of antigen for the COVID-19 vaccine began at the Mabion production plant in Konstantynów Łódzki. The first batch of the key ingredient in the new EU-approved vaccine by Novavax has already been developed near Łódź.

The biotechnological company Mabion is the first Polish company to join the global COVID-19 vaccine production process, thanks to signing an agreement with the American company Novavax for the production of a technical series of protein antigen for a vaccine in March last year.

Arkadiusz Słomczyński